Activated protein C resistance acquired through liver transplantation

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 3, 2005, Pages 215-216

  Pushkaran, Beena ^a   Adams, David ^b   Chapman, Roger ^a   Keeling, David ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Factor V Leiden; Liver transplantation; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTICLE; CASE REPORT; GENETIC ANALYSIS; HEMOPHILIA; HERITABILITY; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOPHILIA;

EID: 17444392443     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000164432.05793.7d     Document Type: Article

References (14)

1. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506.
2. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522.
3. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-1993.
4. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-1508.
6. Parker J, Pagliuca A, Kitiyakara T, Whitehead M, Heaton N, O'Grady J, Arya R. Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation. Blood 2001; 97:2525-2526.
7. Estelles A, Villa P, Mira Y, Vaya A, Segui R, Aznar J. Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia. Haematologica 2000; 85:111-112.
8. Hirshfield G, Collier JD, Brown K, Taylor C, Frick T, Baglin TP, Alexander GJ. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transplant Surg 1998; 4:58-61.
9. Solano C, Self MJ, Cobcroft RG. Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant. Blood Coagul Fibrinolysis 2001; 12:325-326.
10. Gillis S, Lebenthal A, Pogrebijsky G, Levy Y, Eldor A, Eid A. Severe thrombotic complications associated with activated protein C resistance acquired by orthotopic liver transplantation. Haemostasis 2000; 30:316-320.
11. De Mitrio V, Marino R, Rendina M, Di Bari L, Francavilla A, Schiraldi O. Is activated protein C resistance following orthotopic liver transplantation a risk factor for venous thrombosis? Blood Coagul Fibrinolysis 1999; 10:211-212.
12. Foster PA, Varma RR. Phenotypic correction of activated protein C resistance following orthotopic liver transplantation. Blood Coagul Fibrinolysis 1996; 7:65-68.
13. Willems M, Sterneck M, Langer F, Jung R, Haddad M, Hagel C, et al. Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation. Liver Transplant 2003; 9:870-873.
14. Leroy-Matheron C, Duvoux C, Van Nhieu JT, Leroy K, Cherqui D, Gouault-Heilmann M. Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. J Hepatol 2003; 38:866-869.